{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:59:51Z","timestamp":1792598391162,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02818-x","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:16:25Z","timestamp":1783296985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Orelabrutinib versus chemoimmunotherapy in treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: a randomized, phase 3 trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Fei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-7477","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuerong","family":"Shuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2770-5150","authenticated-orcid":false,"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoming","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaibo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weige","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renbin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8621-4840","authenticated-orcid":false,"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"2818_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps, T. J. et al. Chronic lymphocytic leukaemia. Nat. Rev. Dis. Prim. 3, 16096 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2818_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek, M., Shanafelt, T. D. & Eichhorst, B. Chronic lymphocytic leukaemia. Lancet 391, 1524\u20131537 (2018).","journal-title":"Lancet"},{"key":"2818_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","volume":"15","author":"JA Burger","year":"2018","unstructured":"Burger, J. A. & O\u2019Brien, S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat. Rev. Clin. Oncol. 15, 510\u2013527 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2818_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman, M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA 329, 918\u2013932 (2023).","journal-title":"JAMA"},{"key":"2818_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"S Sharma","year":"2019","unstructured":"Sharma, S. & Rai, K. R. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. Cancer 125, 1432\u20131440 (2019).","journal-title":"Cancer"},{"key":"2818_CR6","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","volume":"100","author":"A Wiestner","year":"2015","unstructured":"Wiestner, A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica 100, 1495\u20131507 (2015).","journal-title":"Haematologica"},{"key":"2818_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41571-024-00956-1","volume":"21","author":"MD Stanchina","year":"2024","unstructured":"Stanchina, M. D. et al. Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat. Rev. Clin. Oncol. 21, 867\u2013887 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2818_CR8","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger, J. A. et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N. Engl. J. Med. 373, 2425\u20132437 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2818_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020","author":"A Lipsky","year":"2020","unstructured":"Lipsky, A. & Lamanna, N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol. Am. Soc. Hematol. Educ. Program 2020, 336\u2013345 (2020).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"2818_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","volume":"14","author":"DA Bond","year":"2019","unstructured":"Bond, D. A. & Woyach, J. A. Targeting BTK in CLL: Beyond Ibrutinib. Curr. Hematol. Malig. Rep. 14, 197\u2013205 (2019).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2818_CR11","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman, J. P. et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395, 1278\u20131291 (2020).","journal-title":"Lancet"},{"key":"2818_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam, C. S. et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 23, 1031\u20131043 (2022).","journal-title":"Lancet Oncol."},{"key":"2818_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon, S. Orelabrutinib: first approval. Drugs 81, 503\u2013507 (2021).","journal-title":"Drugs"},{"key":"2818_CR14","doi-asserted-by":"publisher","first-page":"CT132","DOI":"10.1158\/1538-7445.AM2020-CT132","volume":"80","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. Abstract CT132: Orelabrutinib, a potent and selective Bruton\u2019s tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties. Cancer Res 80, CT132\u2013CT132 (2020).","journal-title":"Cancer Res"},{"key":"2818_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","volume":"21","author":"H Yu","year":"2021","unstructured":"Yu, H. et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B-cell lymphoma. Mol. Ther. Oncolyt. 21, 158\u2013170 (2021).","journal-title":"Mol. Ther. Oncolyt."},{"key":"2818_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/17460441.2023.2236547","volume":"18","author":"P Robak","year":"2023","unstructured":"Robak, P., Witkowska, M., Wolska-Washer, A. & Robak, T. The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies. Expert Opin. Drug Discov. 18, 1065\u20131076 (2023).","journal-title":"Expert Opin. Drug Discov."},{"key":"2818_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.26826","volume":"98","author":"W Xu","year":"2023","unstructured":"Xu, W. et al. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. Am. J. Hematol. 98, 571\u2013579 (2023).","journal-title":"Am. J. Hematol."},{"key":"2818_CR18","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","volume":"7","author":"LJ Deng","year":"2023","unstructured":"Deng, L. J. et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study. Blood Adv. 7, 4349\u20134357 (2023).","journal-title":"Blood Adv."},{"key":"2818_CR19","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ajh.27064","volume":"98","author":"L Deng","year":"2023","unstructured":"Deng, L. et al. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. Am. J. Hematol. 98, 1742\u20131750 (2023).","journal-title":"Am. J. Hematol."},{"key":"2818_CR20","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1080\/14656566.2022.2144218","volume":"23","author":"D Gu","year":"2022","unstructured":"Gu, D., Li, J. & Miao, Y. Evaluating orelabrutinib as a novel treatment option for relapsed\/refractory chronic lymphocytic leukemia in China. Expert Opin. Pharmacother. 23, 1979\u20131986 (2022).","journal-title":"Expert Opin. Pharmacother."},{"key":"2818_CR21","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach, J. A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl. J. Med 379, 2517\u20132528 (2018).","journal-title":"N. Engl. J. Med"},{"key":"2818_CR22","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr, P. M. et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 6, 3440\u20133450 (2022).","journal-title":"Blood Adv."},{"key":"2818_CR23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","volume":"36","author":"JP Sharman","year":"2022","unstructured":"Sharman, J. P. et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia. Leukemia 36, 1171\u20131175 (2022).","journal-title":"Leukemia"},{"key":"2818_CR24","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer, K. et al. Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. N. Engl. J. Med 380, 2225\u20132236 (2019).","journal-title":"N. Engl. J. Med"},{"key":"2818_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-021-00862-z","volume":"22","author":"GF Perini","year":"2021","unstructured":"Perini, G. F., Feres, C. C. P., Teixeira, L. L. C. & Hamerschlak, N. BCL-2 Inhibition as treatment for chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 22, 66 (2021).","journal-title":"Curr. Treat. Options Oncol."},{"key":"2818_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32\u201342 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2818_CR27","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","volume":"106","author":"CS Tam","year":"2021","unstructured":"Tam, C. S. et al. Zanubrutinib monotherapy for patients with treatment na\u00efve chronic lymphocytic leukemia and 17p deletion. Haematologica 106, 2354\u20132363 (2021).","journal-title":"Haematologica"},{"key":"2818_CR28","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/ajh.27303","volume":"99","author":"S Yan","year":"2024","unstructured":"Yan, S. et al. A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia. Am. J. Hematol. 99, 1392\u20131395 (2024).","journal-title":"Am. J. Hematol."},{"key":"2818_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101682","volume":"52","author":"XX Cao","year":"2022","unstructured":"Cao, X. X. et al. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. EClinicalMedicine 52, 101682 (2022).","journal-title":"EClinicalMedicine"},{"key":"2818_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/17474086.2022.2067526","volume":"15","author":"BW Christensen","year":"2022","unstructured":"Christensen, B. W., Zaha, V. G. & Awan, F. T. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Expert Rev. Hematol. 15, 321\u2013331 (2022).","journal-title":"Expert Rev. Hematol."},{"key":"2818_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01102-1","volume":"23","author":"M Sestier","year":"2021","unstructured":"Sestier, M., Hillis, C., Fraser, G. & Leong, D. Bruton\u2019s tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation. Curr. Oncol. Rep. 23, 113 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"2818_CR32","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek, M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745\u20132760 (2018).","journal-title":"Blood"},{"key":"2818_CR33","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02818-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02818-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02818-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:16:26Z","timestamp":1783296986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02818-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2818"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02818-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xinran Tang, Weige Wang, and Renbin Zhao are employees of InnoCare Pharma Limited. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}